AIM ImmunoTech (STU:HXB2) Debt-to-Revenue : 20.82 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

AIM ImmunoTech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.71 Mil. AIM ImmunoTech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.37 Mil. AIM ImmunoTech's annualized Revenue for the quarter that ended in Mar. 2024 was €0.15 Mil. AIM ImmunoTech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 20.82.

AIM ImmunoTech Debt-to-Revenue Historical Data

The historical data trend for AIM ImmunoTech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Debt-to-Revenue Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

45.57

14.02

1.11

5.94

3.56

AIM ImmunoTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															4.13	4.75	4.09	2.74	20.82

Competitive Comparison of AIM ImmunoTech's Debt-to-Revenue

For the Biotechnology subindustry, AIM ImmunoTech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Debt-to-Revenue falls into.

AIM ImmunoTech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

AIM ImmunoTech's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0.204	+	0.454)	/	0.185
	=	3.56

AIM ImmunoTech's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.714	+	1.368)	/	0.148
	=	20.82

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

AIM ImmunoTech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines